Ferreira Michelli Erica Souza, Gomes Margarete do Socorro Mendonça, Vieira José Luiz Fernandes
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pará, Belém, PA.
Rev Soc Bras Med Trop. 2011 Jan-Feb;44(1):113-5. doi: 10.1590/s0037-86822011000100026.
Primaquine can produce adverse reactions as toxicity to blood when used in the treatment of vivax malaria. This work aimed to determine methemoglobinemia in patients with vivax malaria receiving oral therapy with primaquine.
Spectrophotometric quantification of methemoglobinemia and qualitative assay for glucose-6-phosphate dehydrogenase.
Methemoglobinemia ranged from 2.85 to 5.45% in male patients and 3.77 to 7.34% in female patients.
A statistically significant increase in methemoglobinemia was observed following oral therapy with primaquine, with no clinical manifestations, and independent of sex and the qualitative expression of glucose-6-phosphate dehydrogenase.
伯氨喹在治疗间日疟时可产生血液毒性等不良反应。本研究旨在确定接受伯氨喹口服治疗的间日疟患者的高铁血红蛋白血症情况。
采用分光光度法定量检测高铁血红蛋白血症，并对葡萄糖-6-磷酸脱氢酶进行定性检测。
男性患者高铁血红蛋白血症范围为2.85%至5.45%，女性患者为3.77%至7.34%。
口服伯氨喹治疗后观察到高铁血红蛋白血症有统计学意义的增加，无临床表现，且与性别及葡萄糖-6-磷酸脱氢酶的定性表达无关。
